PharmNovo strengthens the team with Project Leader/COO
PharmNovo boosts its organisational capacity as Jesper Kjerulff returns to the company as Project Leader and Chief Operations Officer (COO), spearheading the development of PN6047, the company's drug candidate for the treatment of neuropathic pain.
PharmNovo announces the return of former Project Leader Jesper Kjerulff to the company, now assuming the roles of Project Leader and COO, effective from the 1st of May.
Jesper Kjerulff has extensive knowledge and experience in strategically and successfully managing drug development, spanning from the preclinical stage to launch.
"Jesper Kjerulff has demonstrated a high level of strategic proficiency, business acumen, and possesses a solid background. With Jesper's deep understanding of the PN6047 project, we consider it a privilege to have him back on our team at PharmNovo as we continue the journey with our candidate compound PN6047," says Per von Mentzer, CEO of PharmNovo.
Jesper Kjerulff previously served as the project leader of the PN6047 project, appointed by the consultancy group KLIFO. His assignment at PharmNovo was also concluded when he departed KLIFO in September last year.
"I am delighted to be back working with the PharmNovo team on this exciting project, and I look forward to seeing it through to completion. I am a firm and dedicated believer in the potential of PN6047, and I am convinced that its unique mode of action has the ability to revolutionise the treatment of neuropathic pain and provide much-needed relief to patients suffering from it," says Jesper Kjerulff.
PN6047 is currently undergoing Phase I clinical trials, and Phase IIa studies are planned for next year.
Jesper Kjerulff holds an MSc in chemical engineering and a PhD in biotechnology from the Technical University of Denmark as well as a BCom from Copenhagen Business School.
Jesper Kjerulff is a highly experienced pharmaceutical project leader including 18 years of work at Lundbeck. He has a strong global background in drug development, covering both early and late stages across the EU, US, China, Japan, and other regions. Additionally, he has extensive experience in navigating interactions with regulatory authorities, including EMA, FDA, PMDA, and CFDA.
For more information, please contact:
Per von Mentzer, CEO
Phone +46 705 44 32 50
Email: per.von.mentzer@pharmnovo.com
About PharmNovo
PharmNovo AB is a clinical-stage pharmaceutical company focused on developing safe and effective drugs for neuropathic pain. In this area, there is currently a lack of sufficient treatments. The company's drug candidate, PN6047, effectively reduces nerve pain in animal models. The company also sees clinical potential in other areas, such as migraine, anxiety/depression, and chronic cough. PharmNovo, headquartered in Medicon Village in Lund, Sweden, was founded in 2008 by Dr Bengt von Mentzer, who has more than 30 years of experience in drug development and pain research at AstraZeneca. The team comprises prominent researchers in academia and industry, and the company has an extensive international network of leading expert advisors. To learn more, visit pharmnovo.com and follow PharmNovo at LinkedIn.
Tags:
